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Abstract
Background: Residential drug rehabilitation is often seen as a treatment of last resort for people with severe
substance abuse issues. These clients present with more severe symptoms, and frequent psychiatric
comorbidities relative to outpatients. Given the complex nature of this client group, a high proportion of
clients seeking treatment often do not enter treatment, and of those who do, many exit prematurely. Given
the highly social nature of residential drug rehabilitation services, it has been argued that social anxieties
might decrease the likelihood of an individual entering treatment, or increase the likelihood of them
prematurely exiting treatment. The current paper reports on the protocol of a Randomised Control Trial which
examined whether treatment of social anxiety prior to entry to treatment improves entry rates and retention
in residential drug rehabilitation.
Method/design: A Randomised Control Trial comparing a social skills treatment with a treatment as usual
control group was employed. The social skills training program was based on the principles of Cognitive
Behaviour Therapy, and was adapted from Ron Rapee’s social skills training program. A permutated block
randomisation procedure was utilised. Participants are followed up at the completion of the program
(or baseline plus six weeks for controls) and at three months following entry into residential rehabilitation
(or six months post-baseline for participants who do not enter treatment).
Discussion: The current study could potentially have implications for addressing social anxiety within
residential drug treatment services in order to improve entry and retention in treatment. The results might
suggest that the use of additional screening tools in intake assessments, a focus on coping with social
anxieties in support groups for clients waiting to enter treatment, and greater awareness of social anxiety
issues is warranted.
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Background
Treatment engagement and retention in residential drug re-
habilitation settings for individuals with substance misuse
and psychiatric comorbidities is variable [1-4]. Studies have
implicated mental health conditions such as social anxiety
as having a negative impact on engagement and retention
[5]. As residential drug rehabilitation is often the last resort
for people with severe substance misuse problems, effective
management of negative prognostic factors would be a sig-
nificant contribution to improved treatment outcomes. In
Australia, as elsewhere, residential drug treatment is gen-
erally provided by Therapeutic Communities (TC). TCs
are intense psychosocial based interventions which are
grounded in the assumption that substance misuse is a
dysfunction of lifestyle and character development involv-
ing the whole person, resulting in a range of inter and
intra personal difficulties, which are most effectively ad-
dressed in long term treatment in a community comprised
of therapists and peers (i.e., other uses) [6,7]. Treatment in
TCs involves clients moving through a number of treat-
ment stages over a six to 15 month period. Each stage is
associated with specific learning objectives, which facilitate
transition to subsequent stages.
Individuals attending residential drug treatment gener-
ally present with increased severity of symptoms e.g., [8]
and incidence of psychiatric co-morbidity e.g., [9] relative
to outpatients, and are more likely to have significant so-
cial problems [10]. Unsurprisingly, individuals with co-
occurring psychiatric disorders are at greater risk of poor
treatment retention e.g., [11,12] than those without such
comorbidities. Thus, given the complex nature of patients
attending TCs, treatment dropout is high. For example,
Polimeni, Moore and Gruenert [13] examined dropout
rates from an Australian TC over a 10 year period and
found that approximately 45% of patients dropped out of
treatment in the first five weeks. Australian Institute of
Health and Workforce Studies revealed that four percent
of patients stay in residential treatment less than one day,
and 40% less than one month [14]. This low rate of reten-
tion is mirrored in data collected in other Western coun-
tries [15,16].
Although the positive treatment efficacy of TCs has been
demonstrated in a number of studies [17,18], the high
drop-out rate of patients in the first few weeks of treatment
is of particular concern, especially in light of a substantial
body of evidence which has found that for residential treat-
ments, client retention of at least three months is associated
with improved outcomes [16,19-22]. It has been suggested
that treatment factors affecting drop-out might differ be-
tween treatment modalities. In an analysis of predictors of
client retention in TCs, Condelli and De Leon [23] found
that clients who spent a significant amount of time with
large groups of people, rather than alone prior to drug use
were more likely to stay longer in treatment. Similarly, in a
retrospective review, Johns, Baker, Webster and Lewin [15]
found that clients who stayed in treatment less than 90 days
were more likely to have reported spending their free time
alone, or with one other person than clients who stayed in
treatment longer than 90 days. It is unsurprising given the
social nature of the TCs, that clients who have previously
experienced difficulties interacting with small to large
groups of people would find the TC environment challen-
ging. Although the previous studies did not examine psy-
chiatric comorbidities, it appears that social anxieties might
be problematic for individuals remaining in residential
treatment due to the highly social nature of the TCs. There
is substantial evidence to suggest that social anxiety and
substance use problems frequently co-exist, and that sub-
stance users with co-occurring social anxiety are signifi-
cantly more impaired than substance users with no
substantial social anxieties see [24]. Thus, it is likely that so-
cial anxieties may impede actual entry into residential treat-
ment for substance dependence. That is, unlike depressive
symptoms which can sometimes increase the likelihood
that an individual seeks substance misuse treatment [25], it
is possible that social anxiety may serve as a barrier to seek-
ing treatment for substance misuse problems, particularly
group or residential treatment. This is not surprising given
the highly social nature of these two treatment modalities.
Social anxiety is pervasive and disabling and is charac-
terised by intense, persistent fear and anxiety of situations
involving social interaction, social evaluation and appraisal
[26]. It has been argued that social anxiety exists on a con-
tinuum, with social anxiety at the mild end of the con-
tinuum, manifesting as shyness, and at the extreme end as
the clinical diagnostic categories of Social Anxiety Disorder
(SAD) in the DSM-5 (APA, 2013) and Social Phobia in the
ICD-10 (WHO, 1992) [World Health Organisation
[WHO], 1992; 27]. The DSM-5 defines SAD as a “marked
fear or anxiety about one or more social situations in which
the individual is exposed to possible scrutiny by others”
(Criterion A; p. 202), with the individual fearing that they
will act in a way or show anxiety symptoms that will lead
to them being negatively evaluated (Criterion B). These
social situations almost always provoke fear or anxiety
(Criterion C), are avoided, or endured with intense fear or
anxiety (Criterion D), with the fear or anxiety reaction be-
ing judged to be out of proportion with the actual threat
posed by the social situation (Criterion E).
According to National Comorbidity Survey data [28,29],
SAD is the most commonly reported anxiety disorder. In
a nationally representative Australian population study,
Teesson, Hall, Lynskey and Degenhardt [30] found that
6.5% of Australian adults met ICD-10 criteria for alcohol
use disorder. Of these individuals, 3.7% met criteria for
SAD, and among individuals who met criteria for SAD,
16.7% met criteria for an alcohol use disorder. Among
adults seeking drug or alcohol treatment, rates of SAD are
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considerably higher, with comorbidity rates of up to 56% re-
ported [31,32]. While the causal relationship remains un-
clear, concurrent social anxiety seems to lead to social
isolation and depression in those recovering from substance
dependency, which in turn increases the likelihood of drug
or alcohol relapse and the reliance on drug use in social sit-
uations i.e., self-medication and tension-reduction; [33].
Thus, individuals with comorbid SAD are at greater risk
of poor treatment retention [11,12] and relapse to sub-
stance misuse than those with substance misuse problems
alone. Furthermore, although depressive symptoms can
be ameliorated to some extent by treatment for sub-
stance misuse alone see [34], social anxiety disorder re-
mains at clinical levels after drug treatment despite
reductions in substance use [35] and has been shown to
be risk factor for relapse [36].
Although most research and treatment models tend to
categorize social anxiety as a categorical phenomenon, it
has been argued e.g., see [37] that social anxiety is better
represented dimensionally. Preliminary evidence supporting
a dimensional conceptualization of social anxiety came
from studies which attempted to form subgroups based on
symptom severity. For example, although Stein, Torgrud
and Walker [38] were able to classify individuals into three
groups based on the number of social situations they feared
(e.g., 1 to 3 social fears, 4 to 6 social fears and 7 to 12 social
fears) they found that disability was related to the number
of situations feared in a continuous manner, which indi-
cated that viewing the number of social fears dimensionally
was potentially more appropriate than viewing them cat-
egorically. Similarly, Vriends, Becker, Meyer, Michael and
Margraf [39] found that when socially anxious individuals
were classified into groups according to symptom severity,
that there was no clear boundary between the subtypes.
More conclusive evidence for the dimensionality of so-
cial anxiety has come from taxometric analyses. Using
data from the National Comorbidity Survey Replication
(NCS-R), Ruscio [40] conducted a number of taxometric
analyses (MAMBAC, MAXEIG and L-Mode) and found
strong support for a dimensional, rather than taxonic
structure. These results were replicated by Crome, Baillie,
Slade and Ruscio [41] whose analyses of both the NCS-R
dataset and the Australian National Survey of Mental
Health (ANSMH) dataset also strongly supported the di-
mensional nature of social anxiety. Importantly, support
for the dimensional nature of social anxiety has also been
found in clinical populations, with Kollman, Brown, Liver-
ant and Hofmann [42] finding support for the dimensional
nature of social anxiety in a sample of 2,035 outpatients
presenting for treatment at a US based anxiety disorder
treatment centre.
From a clinical perspective, the usefulness of considering
social anxiety dimensionally was demonstrated by Ruscio
[40] who found that dimensional SAD was a better
predictor than categorical SAD of a number of outcomes,
including subsequent suicide ideation, mood disorders, and
treatment seeking behaviours. From the perspective of alco-
hol use, Crum and Pratt [43] found that individuals with
subclinical social anxiety symptoms were more likely to
have drinking problems than those with a clinical diagnosis
of SAD, indicating consideration of social anxiety as a di-
mensional, rather than categorical phenomenon might be
especially important in research exploring social anxiety
and alcohol and substance use disorders.
Taken together, the results of these studies is that differ-
ences between shyness, social anxiety, and avoidant person-
ality disorder are quantitative, rather than qualitative
(although for an alternative position, see [44]). These results
have implications for clinical research on social anxiety and
suggest that an exclusive focus on individuals who meet
DSM criteria for SAD is not clinically warranted. Moreover,
as Kollman, Brown, Liverant and Hofmann [42] note, it also
suggests that social anxiety ought to be assessed using con-
tinuously, rather than forced choice measurements.
Currently, social anxiety in individuals seeking treatment
for substance misuse social anxiety is poorly detected [45]
and inadequately treated within alcohol and drug treatment
settings [46]. Indeed, very few studies have attempted to ad-
dress social anxiety in individuals presenting for substance
use disorders [33]. This highlights the possible need for tar-
geted treatment for individuals with social anxiety and co-
morbid substance misuse. Given that social anxiety may
play a role in an individual deciding not to commence or
continue residential treatment, it is argued e.g., [47] that ad-
dressing social anxiety symptoms prior to and/or at the
early stages of treatment could improve treatment retention
in individuals with comorbid social anxiety and substance
misuse problems. Considering the complex nature of the
relationship between SAD and substance misuse, it is un-
clear how to proceed when treating SAD in individuals with
substance misuse problems. Specifically, it is unclear if SAD
should be treated first or concurrently with treatment for
substance misuse problems. Currently, only two RTCs have
explored the efficacy of treating SAD in substance use pop-
ulations [5,48].
The first study [5] involved individuals seeking treatment
for alcohol use problems who met criteria for both alcohol
misuse and SAD. Individuals were randomised into one of
two treatment conditions, receiving either a 12 week indi-
vidual cognitive behavioural therapy (CBT) intervention
targeting the alcohol problem only or a 12 week individual
CBT treatment targeting both alcohol misuse and social
anxiety problems (which they referred to as the dual
group). In the alcohol only intervention group, treatment
sessions lasted 60 minutes. In the dual group, both alcohol
and social anxiety was covered in each session (beginning
with alcohol and ending with social anxiety). Unexpectedly,
there were no differences between the alcohol only and
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dual intervention groups on social anxiety symptom sever-
ity. Furthermore, the dual intervention group reported
poorer alcohol-related outcomes compared to the alcohol
only intervention group. The authors noted that a limita-
tion of their methodology was the somewhat segregated
approach to treating both disorders. Specifically, the con-
current sessions were divided into two sections during the
one treatment session: treatment of the alcohol problem,
followed by CBT for social anxiety. The effectiveness of
this temporal within-session sequence was questioned by
the authors and it was noted that the literature is unclear
on the best approach.
A second study [48] compared the efficacy of an inten-
sive psychosocial relapse-prevention program delivered on
its own or in combination with an anxiety treatment pro-
gram comprising CBT and optional pharmacotherapy (i.e.,
selective serotonin re-uptake inhibitors; SSRI). Although
the addition of the anxiety treatment program did result
in significant reductions to anxiety symptoms and avoid-
ance, the program was not associated with concomitant re-
ductions in alcohol relapse rates. Despite this, there was a
non-significant trend for the combined treatment to be as-
sociated with a greater likelihood of abstinence of at least
30 days relative to the alcohol only intervention group, with
an effect size of 0.13. It has recently been noted, however
that the small sample size might have meant that the study
was underpowered [49].
Taken together, there is some evidence to suggest that
treatment of social anxiety in treatment seeking substance
users results in reductions in anxiety symptoms, however,
the effects on substance misuse are less clear. Currently,
there are no studies which examine whether addressing
social anxiety prior to treatment improves rate of treat-
ment entry and subsequent treatment retention. This is
important, because as noted earlier, length of tenure in TC
treatment is a significant predictor of improved treatment
outcomes. Thus, the focus of the current study is on
examining whether addressing social anxiety symptoms
prior to entry for residential treatment improves the likeli-
hood that individuals will enter and stay in treatment. A
secondary goal, in line with previous clinical studies, is to
explore if treatment of social anxiety results in concomi-
tant reductions in other indices of psychological distress
(e.g., depression and general levels of anxiety).
The current study utilises a randomised control design
which adheres to CONSORT guidelines [50]. The inter-
vention group receives four sessions of treatment for so-
cial anxiety symptoms, plus boosters, and the control
group remain on the waiting list for entry into residential
treatment (as a treatment as usual group). The proposed
treatment program for SAD is based on Rapee’s [51] pro-
gram “Overcoming Shyness and Social Phobia: A Step by
Step Guide”. This treatment approach involves a range of
standard empirically validated methods for addressing
social anxiety disorder symptoms, including: attention
training, cognitive restructuring, exposure to feared situa-
tions and realistic feedback of social performance. Rapee’s
[51] program focuses on setting ‘homework’ for clients, pri-
marily on restructuring beliefs about social situations into
more realistic terms. It is designed to be undertaken as ei-
ther ‘pure self-help’ or ‘therapist augmented self-help’
where clinicians help ‘problem-solve’ the program’s con-
cepts with a specific focus on each client’s personal context
[52] Two RCTs support the effectiveness of the program in
reducing social anxiety symptoms and other related psy-
chological problems [52,53].
The current study sought to examine whether treat-
ment of social anxiety prior to entry to treatment would
increase the likelihood that individuals would enter, and
subsequently remain in treatment for at least three
months. Additionally, the current study focusses on
whether brief treatment of social anxiety would result in
significant reductions in social anxiety symptom sever-
ity over time, and significant reduction in other indices
of psychological distress.
Research objectives
Primary hypotheses
1. It is hypothesised that individuals in the intervention
group will be more likely to enter the TC than
individuals in the control group.
2. It is hypothesised that individuals in the
intervention group will be more likely than
individuals in the control group to stay in treatment
for at least three months.
Secondary hypotheses
1. It is hypothesised that participants in the
intervention group will report significant reductions
in social anxiety severity between baseline (T1) and
post-intervention (T2) assessments.
2. It is hypothesised that among participants who met
Mini criteria for SAD at baseline (T1), that significantly
more participants in the intervention group will no
longer meet criteria for SAD at the three month
follow-up (T3) relative to the control group.
3. It is hypothesised that participants in the
intervention group will report significantly fewer
symptoms of anxiety and depression following
treatment of social anxiety than participants in the
control group.
Method/design
Study design
The study design is a randomised control trial where the
intervention is being compared to treatment as usual.
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Enrolment is conducted at Odyssey House Victoria (OHV),
an addiction treatment facility located in Melbourne,
Australia. Enrolment commenced June 2010 and is on-
going. All procedures are conducted in accordance with the
Australian Code for the Responsible Conduct of Research
and were approved by the Deakin University Human
Research Ethics Committee.
Study participants and treatment setting
Participants are individuals who apply for entry to a
therapeutic community (TC) based residential rehabilita-
tion treatment program provided through OHV for alco-
hol and substance use problems.
Procedure
The following sections describe the Study procedure.
See Figure 1 for an overview.
Initial screening
Intake assessments are conducted at OHV in order to de-
termine client suitability for treatment. As part of the
standard intake assessment clients complete the self-report
version of the Liebowitz Social Anxiety Scale – Self-Report
version (LSAS [54]). If the client meets eligibility for the
study the intake team provides them with information
about the study and offers that an independent research
team member could contact them to provide information
on the study. Given the self-report format employed, only
clients who attended intake assessments in person were
given an LSAS to complete, and the LSAS was not offered
in the case of phone interviews. The LSAS was offered to
clients who are new to OHV, as well as those who had pre-
viously been residents but who are seeking re-entry into the
program due to relapse.
Inclusion criteria
1. Participants need to be deemed eligible for entry
into the TC by OHV clinicians.
2. Participants must meet criteria for substance
dependence or alcohol dependence as defined by the
DSM-IV-TR [55].
3. On the basis of the strong support for the
dimensional nature of social anxiety (e.g., [41,42])
and on evidence suggesting that individuals with sub
threshold social anxiety are particularly vulnerable to
substance use problems , the decision was made to
base study inclusion on a dimensional scale, rather
than on a diagnosis of SAD. For inclusion in the
study, participants must report sub clinical levels of
social anxiety as measured by the LSAS. Specifically,
they must report at least one moderate symptom of
social anxiety and report avoidance of at least one
situation. This is consistent with Merikangas,
Avenevoli, Acharyya, Zhang, and Angst [56] who
indicated that this level of symptomatology
represented sub clinical levels of social anxiety.
Exclusion criteria
1. Participants are excluded in they are under the age
of 18 years
2. Participants are excluded if there is evidence of
florid or active psychosis
3. Participants are excluded if they report current,
severe suicidality
4. Participants are excluded if they are unable to
read English.
Participants who meet the inclusion criteria were invited
to participate in the study. Participants were advised that
their participation is optional and would not affect their
eligibility or wait time for the rehabilitation program.
Baseline assessment (T1)
Baseline assessments are administered using a standar-
dised protocol. All researchers received prior training
on the instruments used in the assessment prior to
Figure 1 Study procedure flowchart.
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conducting interviews. In addition, new research offi-
cers conducted a number of practice assessments with a
clinical psychologist at OHV prior to working with cli-
ents. The first assessment conducted by new research
officers was also co-administered by a clinical psychologist
at OHV, in order to ensure adherence to the assessment
protocol, and to assess interrater agreement. Research offi-
cers are fully briefed as to the requirements associated
with duty of care, and are made aware of the safety proto-
cols outlined by OHV. Given the time commitment asso-
ciated with the baseline (approximately 1 ½ - 2 hours)
participants are reimbursed with a $25 retail voucher. For
a list of measures used in the baseline assessment, see
Table 1.
Randomisation
Following the baseline interview, an independent researcher
randomises participants to either the intervention or con-
trol group. A permuted block randomisation procedure is
utilised (e.g., Altman et al., 2001) whereby participants are
allocated to the intervention or control group through the
use of a randomly generated number. The permuted blocks
are organised in groups of four (e.g., AABB, ABAB, BBAA)
the details of which are not known by investigators involved
with the administration of the trial. A random number se-
quence is generated which indicates the block of four con-
ditions to be utilised for the following four cases. The use
of the permuted block randomisation process ensures that
intervention group numbers are balanced at the end of
each block and is thus the recommended process in studies
with smaller samples (i.e., n < 100).
Intervention group
Participants in the intervention group receive the Social
Skills Training Program adapted from Rapee’s training pro-
gram. The program was developed in consultation with Pro-
fessor Rapee. The program consists of two individual and
two group sessions held at OHV. Group sessions include a
maximum of four participants. When there are insufficient
currently enrolled participants to form a group, the final two
sessions are conducted as individual sessions. All sessions
are approximately one hour long. One month after the final
intervention session, if clients have not entered the TC, a
booster session is run, which involves a brief 15 minute re-
view of the content of the four sessions, and is conducted by
the clinical psychologist. If the client has not entered the TC
a month after the first booster session, a second booster ses-
sion is conducted. Once clients have entered the TC, two
booster sessions are run within the first month of a client’s
tenure at the TC. Booster sessions at the TC follow the same
format as those conducted prior to entry to the TC.
The sessions are facilitated by a registered and experi-
enced psychologist and conducted according to a struc-
tured manual that includes handouts and information
sheets. Sessions are conducted while the participant is on
the wait list for entry into the TC. The average time be-
tween sessions was one week.
The program material was developed using principles of
cognitive behaviour therapy and was guided by the work of
Rapee (1998). The program content included; social anxiety
psychoeducation, cognitive challenging, reality testing and
attention training (Rapee, 1998). In addition, planning for
challenges/setbacks that may arise prior to or upon entry
into the TC is a facet of the later sessions. Each session is
structured to optimise coverage of the topic material and a
specific checklist of session goals is used by the clinician
during each phase of the intervention. At the end of each
session the client completes a measure assessing their abil-
ity to concentrate as well as their attitudes towards the ses-
sion content. Participants are also asked to complete
homework assignments which are reviewed at the begin-
ning of each session. Table 2 outlines the content covered
in the four sessions.
Therapist adherence
All therapists underwent training in the administration of
the Social Skills Training Program. All sessions are re-
corded in order to monitor content and competency. Par-
ticipants provided verbal consent to be recorded and are
not identified by name during the session. The therapists
have regular meetings with a registered clinical psychologist
with recognised clinical supervision qualifications and ex-
pertise in the cognitive-behavioural treatment of social anx-
iety. At the conclusion of the study, a random sample
(10%) of recorded interviews will be reviewed to monitor
content and competency.
Table 1 Measures administered at each assessment
Measure Baseline
(T1)
Post intervention
(T2)
Follow-up
(T3)
Demographic questions ✓ - ✓
TLFB ✓ - ✓
MINI ✓ - ✓a
ASSIST ✓ - ✓
LSAS ✓ ✓ ✓
BAI ✓ ✓ ✓
BDI ✓ ✓ ✓
CMR ✓ ✓ -
CSQ-8 - ✓b -
Note. TLFB = Timeline Follow-back Method, MINI = Mini International
Neuropsychiatric Interview, ASSIST = Alcohol, Smoking and Substances
Involvement Screening Test, LSAS = Liebowitz Social Anxiety Scale, BAI = Beck
Anxiety Inventory, BDI = Beck Depression Inventory-II, CMR = Circumstances,
Motivation and Readiness for Treatment Scale, CSQ-8 = Client
Satisfaction Questionnaire-8.
aonly modules F, I and J are administered. bonly administered to
intervention clients.
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Control group
Participants in the control group receive an information
sheet restating the standard protocol of admission pro-
cedures to the TC and encouraging them to attend the
preparation sessions which is standard for all partici-
pants waiting to enter. Participants in the control group
also receive a brief information on the definitions of
anxiety (e.g., symptoms, prevalence). The time between
the administration of the initial baseline assessment and
admission into the TC varied.
Post intervention assessment (T2)
At the conclusion of the fourth session participants in
the intervention group complete a post intervention as-
sessment. Participants in the control group complete the
same assessment six weeks after their baseline assess-
ment. In this post intervention assessment, participants
answer qualitative questions relating to the information
received in each condition. In the event that a partici-
pant enters the TC prior to completion of the post
intervention measure, assessment is conducted at the TC.
For a list of measures used in the T2 assessment, see
Table 1.
Follow up assessment (T3)
Three months after entering the TC, all intervention and
control group participants are asked to complete a follow
up interview, which includes qualitative questions relating
to their time spent at the TC. In instances where a client
does not enter the TC, the T3 is administered six months
after the baseline assessment. For a list of measures used
in the T3 assessment, see Table 1.
Measures
Assessment information for this study was drawn from
semi-structured clinical interviews and self-report ques-
tionnaires. In addition clinicians trained in mental health
assessment administered standardised questionnaires and
clinical assessment tools. A list of measures used at each
assessment point is provided in Table 1.
Clinician administered measures
Demographic questionnaire
A basic demographic questionnaire was used to capture cli-
ent characteristics and included questions relating to age,
education, socio-economic status as well as personal and fa-
milial history of substance use and mental health issues.
Mini International Neuropsychiatric Interview
The MINI [57] is a short, structured diagnostic interview,
used to diagnose depression, anxiety, psychotic and sub-
stance use disorders from DSM-IV criteria. It takes approxi-
mately 15 minutes to administer and uses a decision logic
tree to assess the major Axis I disorders in the DSM-IV-TR
and ICD-10. The MINI is reported to demonstrate high
reliability and good concordance with other diagnostic
measures such as the Composite International Diagnostic
Interview and Structured Clinical Interview DSM-III-R-
Patients [57,58]. The MINI was administered at T1 to
clinically assess all potential diagnoses identified from the
MINI-Screen. All participants are administered the sec-
tions assessing social anxiety disorder, antisocial personal-
ity disorder, alcohol use and substance use disorder. The
social anxiety, alcohol use and substance use disorder sec-
tions of the MINI are also administered at T3.
Alcohol, Smoking and Substances Involvement Screening
Test (ASSIST)
The ASSIST [59] is a reliable and valid screening test for
problematic or risky substance use. Eight questions assess
cannabis, cocaine, amphetamines, inhalants, sedatives, hal-
lucinogens, opiates and other miscellaneous drugs, alcohol
and tobacco use within the context of a more general
health and lifestyle-screening interview. Australian research
Table 2 Overview of social skills training program
Session Content
Session 1: psychoeducation • Introduction
• Provide therapy rationale anxiety
and social anxiety psychoeducation
• Introduce and personalise model
of social anxiety
Session 2: cognitive model • Review model of social
anxiety & treatment rationale
• Introduce importance of
realistic/helpful thinking
• Generate unhelpful/unrealistic
thoughts with client
• Introduce more realistic/helpful thinking
Session 3: attention and
behavioural experiments
• Group introduction and guidelines
• Review rationale and goals
for social anxiety group
• Review cognitive component
and model of social anxiety
• Introduce attention
training/breathing exercise
• Conduct attention
behavioural experiments
Session 4: review and
relapse prevention
• Review week and homework
• Review social anxiety model
• Review treatment components
• Discuss nature of recovery
and relate to upcoming challenges
• Relapse prevention planning
• Administer post-intervention
questionnaires
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indicates that it is a valid screening test for substance use in
individuals who use a number of substances and have vary-
ing degrees of substance use [60].
Timeline Follow-Back method (TLFB)
The TLFB [61] measure was used to determine quantity
and frequency of alcohol and drug use. The TLFB is an
established calendar-based assessment tool created to as-
sist client recall of substance consumption over a desired
time period using date-based memory triggers. Use in
the previous 90 days was recorded.
Self-report measures
Liebowitz Social Anxiety Scale (LSAS)
The LSAS [54] is a 24 item scale assessing levels of fear
and avoidance across a range of social and performance
interaction situations. Items are rated on a four point
scale, with higher scores indicative of more severe social
anxiety. SAD is determined by an empirically-derived cut-
off score e.g., [29,62]. The LSAS has been found to possess
acceptable psychometric properties [63], and has been
found to be sensitive to changes in social anxiety following
treatment. Although originally used as a clinician adminis-
tered scale, research has shown the self-report version to
be equivalent [64].
Beck Anxiety Inventory (BAI)
The BAI [65] is a 21- item measure of the severity of anx-
iety in psychiatric populations. Participants rate the severity
of each symptom of anxiety on a 4-point Likert scale (0 =
not at all, to 3 = severely - I could barely stand it). Items are
summed for a total score. The BAI demonstrates good in-
ternal consistency, test-retest reliability and convergent val-
idity with Hamilton Anxiety Rating Scale–Revised (Beck
et al., [65]).
Beck Depression Inventory-II (BDI)
The BDI [66] consists of 21 items measuring common
symptoms of depression on a 4-point Likert scale (0 = not
at all, to 3 = severely - I could barely stand it). Items are
summed for a total score. The BDI demonstrates high in-
ternal consistency, test-retest reliability and convergent
validity with the Hamilton Rating Scale for Depression–
Revised [67]
Circumstances, Motivation and Readiness for Treatment
Scale (CMRS)
The CMRS is a 20 item scale [68] developed as a self-
report scale of client perceptions across four interrelated
domains: circumstances (external pressure), motivation
(intrinsic pressure), readiness and suitability for residential
treatment. Scale items are rated on a 5-point likert scale
from 1 (Strongly Disagree) to 5 (Strongly Agree) with the
option to select N/A if the question does not apply to the
respondent. The CMRS was found to have acceptable in-
ternal consistency (.87 for the total scale), and was found
to be predictive of treatment durations of longer than
30 days.
Client Satisfaction Questionnaire-8 (CSQ-8)
The CSQ-8 [69] is an 8-item questionnaire designed to
measure client satisfaction with a particular health-care
service, and was used to evaluate how satisfied the cli-
ents were with the social anxiety intervention. The CSQ-
8 has good internal reliability, ranging from .83 to .93;
while high construct validity has also been demonstrated
[69]. The CSQ-8 has been translated into 15 different
languages, and is utilised across a wide range of popula-
tions and health services [69].
Qualitative questions
In addition to the structured measures, qualitative ques-
tions developed specifically for the study are asked at T2
and T3. These questions focused on the expectations of
the participant and their opinion of the intervention
program and treatment program at the TC.
Data analysis
1. Differences between the intervention and control
groups in categorical DVs (entry to the TC, TC stays of
at least 30 days, 45 days and 90 days) will be analysed
using binary logistic regression chi-square analysis.
2. Differences between the intervention and control
groups in time spent at the TC will be analysed
using Analysis of Variance, and Cox Proportionate
Hazard Models.
3. Differences between the intervention and control
groups in psychological outcomes over time (i.e.,
LSAS, BDI and BAI) will be explored using linear
mixed modelling. In order to select the appropriate
correlation structure for each of these DVs, linear
models will initially be fitted using one of three
possible correlation structures; compound symmetry
(non-zero uniform correlations and uniform
variance between time points), first order auto-
regressive (observations closers in time are more
highly correlated than observations further apart),
and scaled identity (uniform variance across time
with zero correlations between time points). The
best fitting model for each outcome variable will be
decided by selecting top fitting models based on
Akaike’s Information Criterion (AIC).
4. Differences between the intervention and control
groups in number of participants who no longer
meet Mini criteria for SAD at the three month
follow-up will be assessed using a 2 (intervention vs.
control group) × 2 (SAD vs. no SAD) chi-square
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analysis. This analysis will only be conducted with
participants who met Mini criteria for SAD at the
baseline assessment (T1).
Power analysis
Power analysis indicates that an overall sample size of
121 is required to detect a medium effect size (approx
.70) at the .05 alpha level using linear techniques
(power = .80). On the basis of a previous study con-
ducted at Odyssey House Victoria [70] it is expected
that approximately 21% will be lost to follow up hence
the target of the current study will be a sample of 146.
Discussion
Individuals presenting for residential drug rehabilitation
programs report substantially worse psychiatric comor-
bidities than outpatients. A large proportion of those
claiming to seek treatment will not enter treatment pro-
grams, and of those who do enter treatment, rates of pre-
mature dropout within the first five weeks of treatment
are high. This is particularly problematic given the body of
evidence suggesting that for residential treatment modal-
ities treatment tenure of at least three months is associ-
ated with substantially better treatment outcomes. Indeed,
some studies have indicated e.g., [71] that it is not until
after the three month period that there emerges a correl-
ation between time spent in treatment and treatment out-
comes. Substantial literature has reported that social
anxieties frequently co-occur with substance use prob-
lems, and that individuals with comorbid social anxiety
and substance use problems have a poorer prognosis than
those with no substantial social anxieties. There is some
preliminary evidence that number, and quality of social
contacts prior to substance use is a significant predictor of
treatment retention. In addition, a number of clinical trials
have explored the effect of treating social anxiety on treat-
ment outcomes, and although there is evidence that such
treatment results in improvements to anxiety symptoms,
this was not related to concomitant reductions in sub-
stance use severity. One of the limitations of these studies,
however, is that they focussed on examining whether
treatment of social anxiety was related to reductions in so-
cial anxiety severity and improvements in substance use
problems, but did not explore the effect of treatment of
social anxiety on entry into treatment and on treatment
retention. Given the substantial literature supporting the
efficacy of TCs in cases where treatment exceeds the three
month threshold, the current study sought to explore
whether treatment of social anxiety prior to entry into
treatment will increase the likelihood of entry into resi-
dential treatment and decrease the likelihood of prema-
ture treatment dropout. The results of the study will have
implications for addressing social anxiety within residen-
tial drug treatment services. The results might suggest that
the use of additional screening tools in intake assessments,
a focus on coping with social anxieties in support groups
for clients waiting to enter treatment, and greater aware-
ness of social anxiety issues among residential rehabilita-
tion staff is warranted.
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